Immuno-Oncology Drugs Market By Drugs Type (Immune Checkpoint Inhibitors (CTL-4 Checkpoint Inhibitor and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, By Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma (Hodgkin’s and Non-Hodgkin’s Lymphoma), Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, Head & Neck Cancers), By Distribution Channel (Retail Pharmacies, Hospitals Pharmacies, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2034

Report Code: PMI10718 | Publish Date: March 2024 | No. of Pages: 189

Global Immuno Oncology Drugs Market Overview

Immuno-Oncology Drugs Market Size was valued at US$ 34.4 billion in 2024 and is projected to grow at a CAGR of 24.3% to reach US$ 249.4 billion by 2034.

Immuno-oncology drugs are those which use patient’s immune system to fight against different type of cancer. Immuno-oncology drugs uses novel drugs such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, and cancer vaccines which that boost the immune system of patients and fight against cancer.

Immuno-Oncology Drugs Market Size Report

                          For More Report Details, Download Free Sample PDF

Global Immuno Oncology Drugs Market Drivers & Restraints

Increasing rate and incidence of cancer is expected to be a major factor which will boost the demand for immune-oncology drugs for its treatment products in market in upcoming time period. For instance, as per the National Cancer Institute, it was estimated that in 2018 1,735,350 new cases of cancer will be diagnosed in the U.S. and 609,640 people will die from the disease.

Furthermore, increasing launches of new immune-oncology drugs in market by key players is also expected to drive the market growth over forecast period. For instance, in 2017, Merck, Sharpe and Dohme launched its immune-oncology drug Keytruda (pembrolizumab) in India for the treatment of advanced melanoma.

Global Immuno Oncology Drugs Market Segmentations & Regional Insights

The immuno-oncology drugs market has been segmented on the basis of drug type, cancer type, distribution channel, and region.

The drug type segment includes immune checkpoint inhibitors (CTL-4 Checkpoint Inhibitor, and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy.

On the basis of cancer type, the immuno-oncology drugs market has been segmented into Non-Small cell lung cancer, acute myeloid leukemia, lymphoma (hodgkin’s and non-hodgkin’s lymphoma), multiple myeloma, breast cancer, ovarian cancer, prostate cancer, colorectal cancer, gastric cancers, glioblastoma, and head & neck cancers.

On the basis of distribution channel, the immuno-oncology drugs market has been segmented in retail pharmacies, hospitals pharmacies, and Other.

On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions.

Global Immuno Oncology Drugs Market Competitive Landscape & Key Players

Key players operating in the immuno-oncology drugs market includes, Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

FAQs

The immuno-oncology drugs market has been segmented on the basis of drug type, cancer type, distribution channel, and region.

Increasing rate and incidence of cancer is expected to be a major factor which will boost the demand for immune-oncology drugs for its treatment products in market in upcoming time period.

Key players operating in the immuno-oncology drugs market includes, Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., Gilead Sciences Inc., Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte.

North America is expected to account major market share as compared to that of other regions.

The high cost of immuno-oncology therapies is a key factor which hampers the growth of the market